Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma

por Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F
Publicado 2016

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma

por Jethava, Y, Mitchell, A, Zangari, M, Waheed, S, Schinke, C, Thanendrarajan, S, Sawyer, J, Alapat, D, Tian, E, Stein, C, Khan, R, Heuck, C J, Petty, N, Avery, D, Steward, D, Smith, R, Bailey, C, Epstein, J, Yaccoby, S, Hoering, A, Crowley, J, Morgan, G, Barlogie, B, van Rhee, F
Publicado 2016

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

por Chavan, S S, He, J, Tytarenko, R, Deshpande, S, Patel, P, Bailey, M, Stein, C K, Stephens, O, Weinhold, N, Petty, N, Steward, D, Rasche, L, Bauer, M, Ashby, C, Peterson, E, Ali, S, Ross, J, Miller, V A, Stephens, P, Thanendrarajan, S, Schinke, C, Zangari, M, van Rhee, F, Barlogie, B, Mughal, T I, Davies, F E, Morgan, G J, Walker, B A
Publicado 2017